Ascendis Pharma (ASND) has released an update. Ascendis Pharma A/S has structured its capital to enable significant growth opportunities, with ...

Ascendis Pharma (ASND) is scheduled to announce Q3 earnings results on Thursday, November 14th, after market close. The ...

In a report released today, Vikram Purohit from Morgan Stanley maintained a Hold rating on Ascendis Pharma (ASND – Research Report), with a price target of $167.00. The company’s shares closed last ...

Adults with hypoparathyroidism treated with TransCon PTH in the phase 3 PaTHway open-label trial extension demonstrated ...

Wedbush analyst Liana Moussatos reiterated a Buy rating on Ascendis Pharma (NASDAQ:ASND) on Monday, setting a price target of $209, which is approximately 33.55% ...

On Monday, Goldman Sachs raised the price target for Ascendis Pharma (NASDAQ:ASND) to $195 from $170, while keeping a Buy rating on the stock. This adjustment follows the U.S. Food ...

The group was led by Casdin Capital, which surged 16 percent last month, according to an investor. This puts its share class that invests only in public securities up more than 40 percent for the year ...

GET MORE AI-GENERATED SIGNALS: November 10, 2024, 17:44 pm ET, BY Jesse F.- Contributor| Editor: Thomas H. Kee Jr. ( Follow ...

Novo Nordisk has partnered with Ascendis Pharma on less frequently dosed drugs for obesity and other metabolic diseases, starting with a once-monthly GLP-1 receptor agonist. The Danish pharma ...

December S&P 500 E-Mini futures (ESZ24) are up +0.14%, and December Nasdaq 100 E-Mini futures (NQZ24) are up +0.01% this morning as investors awaited crucial U.S. producer inflation data, remarks from ...